Enzo Life Sciences, a subsidiary of Enzo Biochem, Inc. has launched a new DNA labeling system aimed at array Comparative Genomic Hybridization (aCGH), a technique that detects alterations in the genome leading to changes in DNA copy number. Traditionally, microarrays have been used to measure gene expression or identify mutations using RNA and DNA samples labeled with a signaling moiety. aCGH is a microarray technology designed to measure the amount of DNA at a specific region of the chromosome.  This technology platform is important for the identification and characterization of chromosomal aberrations that underlie cancer and developmental abnormalities.  Chromosomal aberrations such as deletions, duplications, and amplifications can be reliably detected using aCGH.

 

Enzo Life Sciences

800.221.7705